Publication: MiR-486-5p specifically suppresses SAPCD2 expression, which attenuates the aggressive phenotypes of lung adenocarcinoma cells
Authors
Wei, Desheng
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia, Departamento de Biologia Celular e Histiologia
publication.page.editor
publication.page.department
DOI
https://doi.org/10.14670/HH-18-463
item.page.type
info:eu-repo/semantics/article
Description
Abstract
. Background. MiR-486-5p expression is
restrained in lung adenocarcinoma (LUAD). However,
much less has been understood on its role in LUAD. We
aimed to explore the biofunctions of miR-486-5p in
LUAD.
Methods. A differential expression analysis based on
The Cancer Genome Atlas-LUAD dataset was done to
screen the differently expressed miRNAs and mRNAs.
MiR-486-5p and SAPCD2 mRNA expression was
analyzed by qRT-PCR, and protein level of SAPCD2
was assayed by western blot. Upregulation and
downregulation of miR-486-5p or SAPCD2 were
achieved by cell transfection. For cell function assays,
the proliferation of cancer cells was examined by MTT
assay. Cell apoptosis was assessed by flow cytometry
and microscopy. Transwell assay was applied to evaluate
cell migration and invasion. A dual-luciferase detection
was employed to determine the miRNA-mRNA targeting
relationship.
Results. MiR-486-5p expression was notably
reduced in LUAD tissue and cell lines. Upregulating
miR-486-5p restrained the anti-apoptotic and
proliferative abilities, as well as cell migratory and
invasive phenotypes in LUAD cells. SAPCD2 was
determined as one target of miR-486-5p. Also, SAPCD2
forced expression was able to attenuate the inhibitory
impacts of miR-486-5p on the malignant phenotypes of
LUAD cells.
Conclusion. MiR-486-5p suppressed cell malignant
progression in LUAD by targeting SAPCD2, suggesting
that the two may be targets for LUAD treatment.
publication.page.subject
Citation
Histology and Histopathology Vol. 37, nº9 (2022)
item.page.embargo
Ir a EstadÃsticas
Este Ãtem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/